Lung Cancer Medicare Access to Precise Testing Act

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6321 Introduced in House (IH)]

<DOC>






119th CONGRESS
  1st Session
                                H. R. 6321

To amend title XVIII of the Social Security Act to require coverage of 
       lung cancer biomarker testing under the Medicare program.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           November 28, 2025

 Mr. Gottheimer (for himself and Mrs. Kiggans of Virginia) introduced 
 the following bill; which was referred to the Committee on Energy and 
  Commerce, and in addition to the Committee on Ways and Means, for a 
 period to be subsequently determined by the Speaker, in each case for 
consideration of such provisions as fall within the jurisdiction of the 
                          committee concerned

_______________________________________________________________________

                                 A BILL


 
To amend title XVIII of the Social Security Act to require coverage of 
       lung cancer biomarker testing under the Medicare program.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Lung Cancer Medicare Access to 
Precise Testing Act''.

SEC. 2. REQUIRING COVERAGE OF LUNG CANCER BIOMARKER TESTING UNDER 
              MEDICARE.

    (a) Coverage.--Section 1861 of the Social Security Act (42 U.S.C. 
1395x) is amended--
            (1) in subsection (s)(2)--
                    (A) in subparagraph (JJ), by adding ``and'' at the 
                end; and
                    (B) by adding at the end the following new 
                subparagraph:
            ``(KK) lung cancer biomarker testing (as defined in 
        subsection (nnn));''; and
            (2) by adding at the end the following new subsection:
    ``(nnn) Lung Cancer Biomarker Testing.--The term `lung cancer 
biomarker testing' means a test furnished on or after January 1, 2027, 
to an individual diagnosed with lung cancer for the identification of 1 
or more specific biomarkers (such as genes, proteins, or other 
molecules) based on the analysis of such individual's tissue, blood, or 
bodily fluids.''.
    (b) Payment.--Section 1833(a)(1) of the Social Security Act (42 
U.S.C. 1395y(a)(1)) is amended--
            (1) by striking ``and (HH)'' and inserting ``(HH)''; and
            (2) by inserting ``, and (II) with respect to lung cancer 
        biomarker testing (as defined in section 1861(nnn)), the amount 
        paid shall be 100 percent of the reasonable charges for such 
        testing'' before the semicolon at the end.
                                 <all>